{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T16:19:21Z","timestamp":1775837961219,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[1998,6]]},"DOI":"10.1006\/exnr.1998.6819","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:46:56Z","timestamp":1032191216000},"page":"334-342","source":"Crossref","is-referenced-by-count":158,"title":["Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease"],"prefix":"10.1006","volume":"151","author":[{"given":"Brian","family":"Henry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/exnr.1998.6819_EN986819RF1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002826-199619030-00002","article-title":"Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect","volume":"19","author":"Ahlskog","year":"1996","journal-title":"Clin. Neuropharmacol."},{"key":"10.1006\/exnr.1998.6819_EN986819RF2","first-page":"347","article-title":"The clinical physiology of side effects in long-term L-dopa therapy","volume":"5","author":"Barbeau","year":"1974","journal-title":"Adv. Neurol."},{"key":"10.1006\/exnr.1998.6819_EN986819RF3","first-page":"294","article-title":"Chronic treatment withl3","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6819_EN986819RF4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0317167100041500","article-title":"Levodopa-induced dyskinesia: Facts and fancy. What dose the MPTP monkey model tell us","volume":"19","author":"Bedard","year":"1992","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1006\/exnr.1998.6819_EN986819RF5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0304-3940(83)90548-7","article-title":"Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity","volume":"25","author":"Bevan","year":"1983","journal-title":"Neurosci. Lett."},{"key":"10.1006\/exnr.1998.6819_EN986819RF6","first-page":"103","article-title":"DOPA-induced \u2018peak-dose\u2019 dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys","volume":"45","author":"Blanchet","year":"1995","journal-title":"J. Neural. Transm. (Supp)"},{"key":"10.1006\/exnr.1998.6819_EN986819RF7","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN","volume":"80","author":"Burns","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/exnr.1998.6819_EN986819RF8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(78)90856-5","article-title":"Long-term treatment of parkinsonism with bromocriptine","volume":"1","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"10.1006\/exnr.1998.6819_EN986819RF9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/bmj.4.5942.442","article-title":"Bromocriptine in parkinsonism","volume":"4","author":"Calne","year":"1974","journal-title":"Br. Med. J."},{"key":"10.1006\/exnr.1998.6819_EN986819RF10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0024-3205(91)90526-H","article-title":"Naloxone reverses L-DOPA induced overstimulation effects in a Parkinson's disease animal model analogue","volume":"48","author":"Carey","year":"1991","journal-title":"Life Sci."},{"key":"10.1006\/exnr.1998.6819_EN986819RF11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.46.6.1548","article-title":"Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease","volume":"46","author":"Carpentier","year":"1996","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6819_EN986819RF12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(87)90041-4","article-title":"Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"79","author":"Clarke","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"10.1006\/exnr.1998.6819_EN986819RF13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-198403000-00005","article-title":"L-Dopa methyl ester: A candidate for chronic systemic delivery of L-Dopa in Parkinson's disease","volume":"7","author":"Cooper","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"10.1006\/exnr.1998.6819_EN986819RF14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism: Chronic treatment with L-dopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/exnr.1998.6819_EN986819RF15","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","article-title":"Levodopa-induced dyskinesias are improved by fluoxetine","volume":"45","author":"Durif","year":"1995","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6819_EN986819RF16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/exnr.1997.6431","article-title":"Enhancement of behavioural response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression","volume":"144","author":"Duty","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1006\/exnr.1998.6819_EN986819RF17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","article-title":"Effect of nondopaminergic drugs onl","volume":"16","author":"Gomez-Mancilla","year":"1993","journal-title":"Clin. Neuropharm."},{"key":"10.1006\/exnr.1998.6819_EN986819RF18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0006-8993(90)90439-I","article-title":"Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat","volume":"514","author":"Graham","year":"1990","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6819_EN986819RF19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00002512-199609030-00001","article-title":"Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease","volume":"9","author":"Henry","year":"1996","journal-title":"Drugs Aging"},{"key":"10.1006\/exnr.1998.6819_EN986819RF20","first-page":"560.3","article-title":"Alpha2","volume":"21","author":"Henry","year":"1997","journal-title":"Soc. Neurosci. Abstract (USA)"},{"key":"10.1006\/exnr.1998.6819_EN986819RF21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0404.1985.tb03173.x","article-title":"Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease","volume":"71","author":"Hoehn","year":"1985","journal-title":"Acta. Neurol. Scand."},{"key":"10.1006\/exnr.1998.6819_EN986819RF22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1523\/JNEUROSCI.05-06-01513.1985","article-title":"Differential visualisation of dopamine and noradrenaline uptake sites in rat brain using3","volume":"5","author":"Javitch","year":"1985","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.1998.6819_EN986819RF23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(76)90728-5","article-title":"Bromocriptine and levodopa (with or without carbidopa) in parkinsonism","volume":"2","author":"Kartzinel","year":"1976","journal-title":"Lancet"},{"key":"10.1006\/exnr.1998.6819_EN986819RF24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/jnnp.44.11.1020","article-title":"Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease","volume":"44","author":"Lees","year":"1981","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1006\/exnr.1998.6819_EN986819RF25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","article-title":"Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report","volume":"307","author":"Lees","year":"1993","journal-title":"Br. Med. J."},{"key":"10.1006\/exnr.1998.6819_EN986819RF26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1056\/NEJM197612162952504","article-title":"Treatment of Parkinson's disease with bromocriptine","volume":"295","author":"Lieberman","year":"1976","journal-title":"N. Eng. J. Med."},{"key":"10.1006\/exnr.1998.6819_EN986819RF27","first-page":"225","article-title":"The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease","volume":"45","author":"Molho","year":"1995","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1006\/exnr.1998.6819_EN986819RF28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia","volume":"40","author":"Nutt","year":"1990","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6819_EN986819RF29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/jnnp.39.11.1101","article-title":"Bromocriptine in parkinsonism: long-term treatment dose response, and comparison with levodopa","volume":"39","author":"Parkes","year":"1976","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1006\/exnr.1998.6819_EN986819RF30","series-title":"The Rat Brain in Stereotatic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1006\/exnr.1998.6819_EN986819RF31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"ChroniclCallithrix Jacchus","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Dis."},{"key":"10.1006\/exnr.1998.6819_EN986819RF32","first-page":"111","article-title":"L-DOPA-induced dyskinesias improvement by an \u03b12","volume":"12","author":"Rascol","year":"1997","journal-title":"Mov. Dis."},{"key":"10.1006\/exnr.1998.6819_EN986819RF33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","article-title":"Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease","volume":"19","author":"Rascol","year":"1996","journal-title":"Clin. Neuropharmacol."},{"key":"10.1006\/exnr.1998.6819_EN986819RF34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.37.5.826","article-title":"Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up","volume":"37","author":"Rinne","year":"1987","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6819_EN986819RF35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.39.3.336","article-title":"Lisuride, a dopamine agonist in the treatment of early Parkinson's disease","volume":"39","author":"Rinne","year":"1989","journal-title":"Neurology"},{"key":"10.1006\/exnr.1998.6819_EN986819RF36","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0140-6736(75)92293-X","article-title":"Dyskinesias during levodopa therapy","volume":"1","author":"Tolosa","year":"1975","journal-title":"Lancet"},{"key":"10.1006\/exnr.1998.6819_EN986819RF37","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1523\/JNEUROSCI.07-09-02927.1987","article-title":"Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilisation in rats with unilateral 6-hydroxydopamine substantia nigra lesions","volume":"7","author":"Trugman","year":"1987","journal-title":"J. Neurosci."},{"key":"10.1006\/exnr.1998.6819_EN986819RF38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system","volume":"24","author":"Ungerstedt","year":"1970","journal-title":"Brain Res."},{"key":"10.1006\/exnr.1998.6819_EN986819RF39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta. Physiol. Scand. Suppl."},{"key":"10.1006\/exnr.1998.6819_EN986819RF40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of parkinsonism with levodopa","volume":"21","author":"Yahr","year":"1969","journal-title":"Arch. Neurol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488698968194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488698968194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T13:39:43Z","timestamp":1576503583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488698968194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["S0014488698968194"],"URL":"https:\/\/doi.org\/10.1006\/exnr.1998.6819","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}